Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

Is Social Isolation an Overlooked Risk Factor in Cancer Mortality? People with cancer who experience loneliness or social ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia/death rates with a 50 mg/m2 biweekly docetaxel regimen. Despite a higher cumulative docetaxel dose ...

Paint Natchez Pink unites the community to honor breast cancer survivors, raise awareness, and highlight the importance of ...

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September ...

As an example, the ALPACA trial took 6.5 years to recruit just 25 patients across three Canadian centers, underscoring the ...

Adani-Ifè, A. , Apélété, A. , Doléagbénou, A. and Djibril, M. (2025) Family Caregiving in Cancer Care in Togo: Tasks, Consequences, and Unmet Needs. Journal of Cancer Therapy, 16, 364-379. doi: ...